The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial.
Anna Maria Di Giacomo
No relevant relationships to disclose
Paolo Antonio Ascierto
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Sharp & Dohme; Roche/Genentech
Honoraria - Amgen; Bristol-Myers Squibb; Roche
Lorenzo Pilla
No relevant relationships to disclose
Ruggero Ridolfi
No relevant relationships to disclose
Mario Santinami
No relevant relationships to disclose
Alessandro Testori
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline
Honoraria - Amgen; Bristol-Myers Squibb; GlaxoSmithKline
Paola Queirolo
Consultant or Advisory Role - GlaxoSmithKline; Roche
Ester Simeone
No relevant relationships to disclose
Massimo Guidoboni
No relevant relationships to disclose
Michele Del Vecchio
Consultant or Advisory Role - Merck Sharp & Dohme; Schering-Plough
Research Funding - Celgene; Novartis; Roche
Pier Francesco Ferrucci
No relevant relationships to disclose
Antonella Marasco
No relevant relationships to disclose
Ester Fonsatti
No relevant relationships to disclose
Diego Annesi
No relevant relationships to disclose
Diana Giannarelli
No relevant relationships to disclose
Giorgio Parmiani
Research Funding - NIBIT(Italian Network for Tumor Biotherapy)
Michele Maio
Consultant or Advisory Role - Bristol-Myers Squibb